

Lorena Incorvaia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2969343/publications.pdf>

Version: 2024-02-01

75
papers

1,550
citations

318942

23
h-index

388640

36
g-index

76
all docs

76
docs citations

76
times ranked

2421
citing authors

#	ARTICLE	IF	CITATIONS
1	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	2.0	26
2	Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1665.	1.3	11
3	The molecular tumor board: a tool for the governance of precision oncology in the real world. <i>Tumori</i> , 2022, 108, 288-290.	0.6	9
4	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	1.4	0
5	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	1.6	17
6	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	0.9	5
7	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations" consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). <i>Radiologia Medica</i> , 2022, 127, 534-542.	4.7	8
8	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 10519-10519.	0.8	0
9	Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21525-e21525.	0.8	2
10	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 172, 191-198.	1.3	8
11	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3
12	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	1.7	14
13	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	1.7	23
14	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. <i>European Radiology</i> , 2021, 31, 8554-8564.	2.3	20
15	Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women. <i>Frontiers in Physiology</i> , 2021, 12, 661464.	1.3	21
16	Current treatment options for HER2-positive breast cancer patients with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103329.	2.0	14
17	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021, 2, 173-196.	0.5	14
18	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
20	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	1.7	6
21	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	2.0	40
22	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13
23	Liquid Biopsy. <i>UNIPA Springer Series</i> , 2021, , 99-122.	0.1	0
24	Biomarkers. <i>UNIPA Springer Series</i> , 2021, , 43-64.	0.1	0
25	Gastrointestinal Stromal Tumors (GISTs). <i>UNIPA Springer Series</i> , 2021, , 1021-1059.	0.1	0
26	Endometrial and Cervical Cancers. <i>UNIPA Springer Series</i> , 2021, , 885-922.	0.1	0
27	Central Nervous System Malignancies. <i>UNIPA Springer Series</i> , 2021, , 731-754.	0.1	0
28	Tumor Board and Molecular Tumor Board. <i>UNIPA Springer Series</i> , 2021, , 401-409.	0.1	0
29	Renal Cancer. <i>UNIPA Springer Series</i> , 2021, , 755-774.	0.1	1
30	Ovarian Cancer: Primary Advanced and Recurrent Disease. <i>UNIPA Springer Series</i> , 2021, , 861-883.	0.1	0
31	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. <i>UNIPA Springer Series</i> , 2021, , 411-416.	0.1	0
32	Soft Tissue Sarcomas (STS). <i>UNIPA Springer Series</i> , 2021, , 1009-1020.	0.1	0
33	Targeted Therapy. <i>UNIPA Springer Series</i> , 2021, , 181-206.	0.1	0
34	Hereditary Cancers and Genetics. <i>UNIPA Springer Series</i> , 2021, , 65-98.	0.1	0
35	S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. <i>Chemotherapy</i> , 2021, 66, 1-8.	0.8	1
36	Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections. <i>American Journal of Surgery</i> , 2020, 220, 359-364.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
38	A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. <i>Cancers</i> , 2020, 12, 3396.	1.7	41
39	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolmmunology</i> , 2020, 9, 1832348.	2.1	55
40	Recent Advances in Desmoid Tumor Therapy. <i>Cancers</i> , 2020, 12, 2135.	1.7	18
41	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. <i>Cancers</i> , 2020, 12, 1899.	1.7	26
42	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. <i>Cancers</i> , 2020, 12, 2415.	1.7	40
43	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily) Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	1.7	30
44	BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097532.	1.4	34
45	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 68-75.	2.0	4
46	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	1.7	4
47	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
48	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	1.4	27
49	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	2.0	51
50	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984887.	1.4	30
51	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	1.4	48
52	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2019, 8, e1561120.	2.1	92
53	One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 3593-3597.	1.0	10
54	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	13

#	ARTICLE	IF	CITATIONS
55	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. Cellular Immunology, 2019, 343, 103753.	1.4	187
56	Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. Radiologia Medica, 2019, 124, 259-265.	4.7	10
57	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. European Journal of Endocrinology, 2019, 181, 681-689.	1.9	30
58	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. Journal of Clinical Oncology, 2019, 37, 11032-11032.	0.8	0
59	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. Journal of Clinical Oncology, 2019, 37, e16109-e16109.	0.8	0
60	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. Oncology, 2018, 95, 1-7.	0.9	7
61	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. Expert Review of Gastroenterology and Hepatology, 2018, 12, 471-478.	1.4	5
62	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	1.0	11
63	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879462.	1.4	27
64	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. Current Cancer Drug Targets, 2018, 18, 697-705.	0.8	34
65	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739.	1.4	20
66	Liquid Biopsy in Gastrointestinal Stromal Tumor. Current Clinical Pathology, 2017, , 151-159.	0.0	1
67	BMI as a risk factor for toxicities in patients with advanced soft tissue sarcoma treated with trabectedin.. Journal of Clinical Oncology, 2017, 35, e22517-e22517.	0.8	0
68	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. Journal of Clinical Oncology, 2017, 35, 11038-11038.	0.8	0
69	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	0.8	36
70	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology, 2016, 107, 20-32.	2.0	31
71	Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report. Cancer Investigation, 2016, 34, 415-423.	0.6	27
72	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. Oncotarget, 2016, 7, 60712-60722.	0.8	103

#	ARTICLE	IF	CITATIONS
73	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	0.8	16
74	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , 2016, 7, 29321-29332.	0.8	23
75	MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. <i>Anticancer Research</i> , 2007, 27, 1519-25.	0.5	58